Plain-English translation of NCT04005469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a medication called can help protect your new kidney right after transplant surgery. When a donated kidney is transplanted, it temporarily loses its blood supply during surgery, and then the blood flow is restored—a process that can cause damage to the organ. Researchers believe this medication, given through an IV line before and after surgery, might reduce that damage and help your new kidney work better.
After a kidney transplant, the period when blood flow is restored to the organ can cause injury that leads to delayed kidney function and complications. This trial is exploring whether this medication's blood vessel-relaxing properties can minimize that injury and improve how well your new kidney functions.
You likely qualify if…
You likely don't qualify if…
You would be hospitalized for the entire two-day treatment period. Starting 2–3 hours before your kidney transplant surgery, the medication would be given continuously through an IV line placed in a central vein. The infusion would continue for about 48 hours after your surgery is complete. During this time, you would be closely monitored by the medical team for safety and how well the treatment is working. The dose would be gradually increased as tolerated, unless side effects prevent that.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States